Prevention of lethal tumor growth and generation of long-lasting immunity in vivo using CD137L and interleukin-12 gene transfer

In Vivo

Volumn 22, Issue 3, 2008, Pages 337-344

  Kim, Young ^a   Strehl, John W ^a   Gorschlüter, Marcus ^a   Ziske, Carsten ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

CD137L; Gene therapy; In vivo; Interleukin 12; Plasnocytoma

Indexed keywords

CD137 LIGAND; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL BASED GENE THERAPY; CONTROLLED STUDY; IMMUNOSTIMULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMACYTOMA; SURVIVAL RATE; TUMOR IMMUNITY;

EID: 45949109804     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bronte V, Cingarlini S, Marigo I, De Santo C, Gallina G, Dolcetti L, Ugel S, Peranzoni E, Mandruzzato S and Zanovello P: Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunol Invest 35: 327-357, 2006.
2. Neeson P and Paterson Y: Effects of the tumor microenvironment on the efficacy of tumor immunotherapy. Immunol Invest 35: 359-394, 2006.
3. Xu DP, Suter BV, Huang TG, Meseck M, Woo SL and Chen SH: The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther 12(20): 1526-1533, 2005.
4. Doehn C, Kausch I, Melz S, Behm A and Jocham D: Cytokine and vaccine therapy of kidney cancer. Expert Rev Anticancer Ther 4: 1097-1111, 2004.
5. Novelli F and Casanova JL: The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev 15: 367-377, 2004.
6. Zhang L, Wang Q, Wang X, Ding P, Soolg J, Ma C and Sun W: Anti-CD137 monoclonal antibody promotes the direct antitumor effect mediated by peripheral blood-derived human dendritic cells in vitro. Cell Mol Immunol. 1: 71-76, 2004.
7. Rabu C, Quemener A, Jacques Y, Echasserieau K, Vusio P and Lang F: Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem 280: 41472-41481, 2005.
8. Salih HR, Kiener PA and Nussler V: 4-1BB-ligand - just another costimulating molecule? Int J Chn Pharmacol Ther 40: 348-353
9. Pardoll DM: Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2: 227-238, 2002.
10. Vinay DS and Kwon BS: Role of 4-1BB in immune responses. Semin Immunol 10: 481-489, 1998.
11. Goodwin RG, Din WS, Davis-Smith T, Anderson DM, Gimpel SD, Sato TA, Maliszewski CR, Brannan CI, Copeland NG and Jenkins NA: Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 23: 2631-2641, 1993.
12. Hurtado JC, Kim YJ and Kwon BS: Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 158: 2600-2609, 1997.
13. Guinn BA, DeBenedette MA, Watts TH and Berinstein NL: 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a longlasting antitumor vaccine. J Immunol 162: 5003-5010, 1999.
14. Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL and Watts'TH: 4-1BBL enhances antitumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. Cell Immunol 210: 56-65, 2001.
15. Trinchieri G: Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Inummol 70: 83-243, 1998.
16. Trinchieri G: Immunobiology of interleukin-12. Immunol Res 17: 269-278, 1998.
17. Melero I, Mazzolini G, Narvaiza I, Qian C, Chen L and Prieto J: IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends 22: 113-115, 2001.
18. Sangro B, Melero I, Qian C and Prieto J: Gene therapy of cancer based on interleukin 12. Curr Gene Ther 5: 573-581, 2005.
19. Schimanski CC, Horner V, Kanzler S, Galle PR and Moehler M: Immunotherapy of colorectal cancer - overview and perspectives. Gastroenterol 44: 673-681, 2006.
20. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS and Chen L: Amplification of tumor immunity by gene transfer of the costimulatory 4-1BB ligand: synergy with the CD28 costiniulatory pathway. Eur J Immunol 28: 1116-1121, 1998.
21. DeBenedette MA, Chu NR, Pollok KE, Hurtado J, Wade WF, Kwon BS and Watts TH: Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by cAMP. J Exp Med 81: 985-992, 1995.
22. Shen HM and Pervaiz S: TNF receptor superfamily-induced cell death: redox-dependent execution. FASEB J 20: 1589-1598, 2006.
23. Giuntoli RL 2nd, Lu J, Kobayashi H, Kennedy R and Celis E: Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 8: 922-931, 2002.
24. Wiethe C, Dittmar K, Doan T, Lindenmaier W and Tindle R: Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 170: 2912-2922, 2003.
25. Wilcox RA, Tamada K, Strome SE and Chen L: Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 169: 4230-4236, 2002.